Nachrichten zur Viking Therapeutics Inc. Aktie

Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.…

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall…

Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous…

Motley Fool 2025 March Market Cap Showdown Championship

It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending…

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

Its hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug…

Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually…

Why Novo Nordisk Stock Outpaced the Market on Tuesday

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little…

An Ozempic successor falls short, Eli Lillys GLP-1 pill, and senators grill RFK: Pharma news roundup

Plus, Eli Lillys CEO got a pay raise, and Viking Therapeutics gets closer to bringing its Ozempic competitor to market…

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from…

Viking Therapeutics: No Buyout Needed Now

…

How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.…

VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity…

Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)

…

Is Eli Lilly Stock a Buy?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and its an element you…

The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They…

This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine…

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous…

Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from…

1 Biotech Stock to Buy in 2025, and 1 to Avoid

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.…

Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Heres 1 Reason Why.

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO)…

Should You Buy VKTX Stock Amid Renewed M&A Speculations?

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.…

Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and Its Not Eli Lilly or Novo Nordisk

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly…

Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going…

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The…

2 Stocks to Buy With Less Than $40

Some think investing in stocks requires substantial start-up capital, but thats false. Even with a modest sum, like $40, investors…

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Healthcare stocks have something to offer every investor. If youre looking for high growth, you can try an innovative biotech…

Viking Therapeutics Aktie: Pipeline-Strategie aktualisiert

Charlotte, NC (www.aktiencheck.de) - Viking Therapeutics-Aktienanalyse von Truist: Aktuelle Bewertung Truist hat das Kursziel für die Aktie von Viking Therapeutics, Inc. (ISIN:…

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

…

2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and…

Has the Bubble Burst for Viking Therapeutics Stock?

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has…

VKTXs Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Viking Therapeutics fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on…

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall…

Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring

…

This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?

Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics.…

Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.…

This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a…

Viking Therapeutics: The Turning Point Is Not Here Yet

…

Viking Therapeutics Aktie: Analysten sehen großes Potenzial dank VK2735

New York (www.aktiencheck.de) - Viking Therapeutics-Aktienanalyse von H.C. Wainwright & Co.: Rating und Kursziel Die Analysten von H.C. Wainwright bewerten die Aktie…

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Streets Bullish Views?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall…

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Streets Bullish Views?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall…

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and its making itself felt all across…

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet…

3 Mid-Cap Stocks That Could Take Off in 2025

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have…

Why Viking Therapeutics Stock Plummeted by 24% in December

Viking Therapeutics (NASDAQ: VKTX) didnt exactly capture investors hearts in the final month of 2024. The biotech companys share price…

Should You Buy the Dip on This High-Flying Stock?

Its been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Thanks to impressive mid-stage clinical results,…

VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics…

3 Stocks That Could Be Monster Winners in 2025

What do many kids like most about the coming of a new year? The fireworks. Investors dont mind seeing some…

Viking Therapeutics Aktie: Kursanstieg nach Novo Nordisks Studiendaten

New York (www.aktiencheck.de) - Viking Therapeutics-Aktienanalyse von BTIG: Aktuelle Bewertung BTIG hat die "buy"-Empfehlung für die Aktie von Viking Therapeutics, Inc. (ISIN:…

Viking Therapeutics Aktie: Enttäuschende Ergebnisse von Novo Nordisks eröffnen Chancen für Wettbewerber

New York (www.aktiencheck.de) - Viking Therapeutics-Aktienanalyse von H.C. Wainwright & Co: Aktuelle Bewertung Die H.C. Wainwright-Analyse betont die positive Entwicklung von Viking…

Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a…